Financial Results First Nine Months 2023

Financial Results First Nine Months 2023

Pillars of growth


Heavy bet for R&D
as a future
growth engine

conocer +


Heavy bet on R&D
as a future
growth engine

find out more

Biosimilar de Enoxaparina


A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

find out more

Especialidades farmacéuticas

Pharmaceutical products

Diversified portfolio of innovative own and licensed products protected by patents.

find out more


Low Molecular Weight Heparin

ROVI's principal product, a low-molecular-weight heparin developed in-house.

find out more

Fabricación a terceros


High production capacity with four the manufacturing plants for prefilled syringes and oral solid forms.

find out more

Rovi en cifras

Rovi in figures

817.7 Mn€

Operatig revenuesin 2022

264.0 Mn€

Sales for the Heparin Division in 2022(+9% vs 2021)

+90 countries

LMWH presence through strategic alliances with international partners

7 plants

For the third party, own and Investigational drug manufacture

403.5 Mn€

CDMO Sales in 2022 (+52% vs 2021)


Porcentage of women on the   Boards of Directors

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to Shareholders and Investors

Last news on Rovi 

(See all items)

Last annual report


Annual report 2022

Last regular
public information


Executive Summary